EUVIMEDEUVIMED entdecken
KohortenstudieOpen Access · CC BY 4.0

Impact of Pulmonary Hypertension on Posttransplant Survival of Patients With Pulmonary Fibrosis at High Altitude: A Prospective Cohort Study

Fabio Varón-Vega iD, Luis J Telléz, Eduardo Tuta-Quintero iD, Adriana Rincón, Diana Casas, Camilo Rodriguez, David Mendoza, Luis Fernando Giraldo-Cadavid iD

Canadian Respiratory Journal · 2025

DOI: 10.1155/carj/1861990 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Canadian Respiratory Journal, 2025. Verfasst von Fabio Varón-Vega und 7 weiteren Autor:innen. Beteiligte Einrichtung: Critical Care and Lung Transplantation Service, Fundación Neumológica Colombiana, Fundación Cardio Infantil-Instituto de Cardiología, Bogotá, Colombi…. Hauptthemen laut MEDLINE: Hypertension, Pulmonary, Lung Transplantation, Pulmonary Fibrosis, Altitude. Die Arbeit nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Fundación Cardioinfantil - Instituto de Cardiología.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Pulmonary hypertension (PH) in patients undergoing lung transplantation (LT) for pulmonary fibrosis can impair lung function, reduce physical activity, and decrease survival. However, data on outcomes at 1 and 5 years of follow‐up remain limited.

Methods

In this prospective cohort study, pulmonary function, the 6‐min walk test (6MWT), and the St. George’s Respiratory Questionnaire (SGRQ) were assessed pretransplant, at hospital discharge, and at 3, 6, and 12 months posttransplant. Additionally, minimal clinically important differences (MCIDs) between patients with and without PH were evaluated. Survival rates were calculated using the Kaplan–Meier method and analyzed using the log‐rank test.

Results

The study included 39 patients undergoing LT for pulmonary fibrosis. Of these, 82% (32/39) had PH, with a median age of 52.6 years (SD: 10.2). In both the PH and non‐PH groups, lung function, 6MWD, and SGRQ total scores showed progressive improvement from pre‐LT to 1 year posttransplant. Patients without PH demonstrated MCID in 6MWT and SGRQ total scores from pre‐LT through the 6‐ and 12‐month follow‐up. The overall 1‐year survival rate was 84.6%, with an average survival of 10.51 months (95% CI: 9.29–11.73). The 5‐year overall survival rate was 61.5%, with an average survival of 44.89 months (95% CI: 37.62–52.16). No statistically significant differences in survival were found based on sex ( p = 0.322 and 0.206), mean pulmonary artery pressure (mPAP) ( p = 0.232 and 0.486), age ( p = 0.375 and 0.959), or body mass index (BMI) ( p = 0.884 and 0.594) at 1 and 5 years.

Conclusion

Survival at 1 and 5 years was lower in patients with PH. However, no significant differences in survival were observed based on sex, mPAP, age, or BMI. Statistically significant improvements in FVC, FEV1, 6MWT, and SGRQ total scores were observed both before and after LT, continuing through 1 year of follow‐up. The 6MWT and SGRQ showed MCID both prior to surgery and during follow‐up at 6 and 12 months, in both PH and non‐PH patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hypertension, PulmonaryLung TransplantationPulmonary FibrosisAltitudeHumansMaleFemaleMiddle AgedProspective StudiesAdultWalk TestSurvival RateRespiratory Function Tests

Stichwörter der Autor:innen

lung transplantpulmonary fibrosispulmonary hypertensionsurvival

Autor:innen und Institutionen

  • Critical Care and Lung Transplantation Service, Fundación Neumológica Colombiana, Fundación Cardio Infantil-Instituto de Cardiología, Bogotá, Colombia.
  • Critical Care Service, Fundación Neumológica Colombiana, Fundación Cardio Infantil-Instituto de Cardiología, Bogotá, Colombia.
  • Thoracic Surgery Service, Fundación Cardio Infantil-Instituto de Cardiología, Bogotá, Colombia.
  • School of Medicine, Universidad de La Sabana, Chía, Colombia.
  • Interventional Pulmonology Service, Fundación Neumológica Colombiana, Bogotá, Colombia.

ORCID-Profile: Fabio Varón-Vega, Eduardo Tuta-Quintero, Luis Fernando Giraldo-Cadavid

Förderung

  • Fundación Cardioinfantil - Instituto de Cardiología

Zitieren

APA

Varón-Vega, F., J Telléz, L., Tuta-Quintero, E., Rincón, A., Casas, D., Rodriguez, C., Mendoza, D., & Giraldo-Cadavid, L. F. (2025). Impact of Pulmonary Hypertension on Posttransplant Survival of Patients With Pulmonary Fibrosis at High Altitude: A Prospective Cohort Study. Canadian Respiratory Journal. https://doi.org/10.1155/carj/1861990

Vancouver

Varón-Vega F, J Telléz L, Tuta-Quintero E, Rincón A, Casas D, Rodriguez C, et al. Impact of Pulmonary Hypertension on Posttransplant Survival of Patients With Pulmonary Fibrosis at High Altitude: A Prospective Cohort Study. Canadian Respiratory Journal. 2025. doi:10.1155/carj/1861990

BibTeX
@article{VarnVega2025,
  author = {Varón-Vega, Fabio and J Telléz, Luis and Tuta-Quintero, Eduardo and Rincón, Adriana and Casas, Diana and Rodriguez, Camilo and Mendoza, David and Giraldo-Cadavid, Luis Fernando},
  title = {Impact of Pulmonary Hypertension on Posttransplant Survival of Patients With Pulmonary Fibrosis at High Altitude: A Prospective Cohort Study},
  journal = {Canadian Respiratory Journal},
  year = {2025},
  doi = {10.1155/carj/1861990}
}
Kostenlos starten →